Regeneron and Telix announced a partnership to enter radiopharmaceuticals, pairing Regeneron’s VelocImmune antibody platform with Telix’s radiopharmaceutical development, manufacturing, and global supply chain capabilities. The collaboration is structured as a 50/50 cost- and profit-sharing model. The companies said they plan to co-develop and co-commercialize next-generation radiopharmaceutical therapies targeting up to eight solid tumor targets from Regeneron’s antibody portfolio, with diagnostic assets to support patient selection and treatment-response assessment. Telix receives an upfront payment tied to four initial therapeutic programs, with options to expand the scope. Regeneron’s move signals a broader push by big pharma into theranostics, while Telix gains access to an established antibody pipeline for new radioligand programs. The deal also underscores the growing emphasis on integrated diagnostics to improve precision oncology execution.